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Purpose: Sleep problems in middle-aged and older women are very common and have been
associated with menopause-related changes in estrogen levels. However, not all women
experience sleep problems as they enter perimenopause, and epigenetic mechanisms might
contribute to the differences in sleep quality within this population. In this study, we
hypothesized that increased methylation of two estrogen receptor (ER) genes (ESR1 and
GPER) would be associated with increased sleep problems in healthy pre-, peri-, and
postmenopausal women, either directly or indirectly through the experience of vasomotor
symptoms (VMS).
Materials and Methods: In 130 healthy women aged 40–73 years, we assessed DNA
methylation from dried blood spots (DBS). Women rated their sleep quality using the
Pittsburgh Sleep Quality Index (PSQI), and VMS using the Menopause Rating Scale (MRS).
Results: Higher percentage methylation of ESR1 was associated with increased sleep
problems, mediated by VMS, even after controlling for age, menopausal status, body mass
index, estradiol levels, depressive symptoms, and caffeine consumption. There was no
significant association between GPER methylation and either sleep problems or VMS.
Conclusion: The study findings support an association between increased ESR1 methylation
and sleep problems through increased VMS among healthy women aged 40–73 years.
Keywords: sleep problems, VMS, ESR1, GPER, DNA methylation, healthy middle-aged
and older women
Introduction
Sleep is an important determinant of quality of life during aging, even among
healthy individuals.1,2 Sleep problems in the form of insomnia, difficulty falling
asleep, lower sleep efficiency, or frequent and early awakening become increasingly
common with advancing age, and affect as many as 40–56% of middle-aged and
older women.3 Menopausal status (MS) is strongly associated with sleep problems,
with peri- and postmenopausal women reporting more sleep problems than pre-
menopausal women.4 Changes in levels of ovarian hormones such as estrogens are
important contributors to the occurrence and severity of sleep problems as women
enter perimenopause.5 Indeed, besides their role in women’s reproductive functions,
estrogens exert a vast range of biological effects. In the central nervous system,
estrogens contribute to the control of circadian rhythms and body temperature,5,6
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and their declining and fluctuating levels have been repeat-
edly associated with sleep problems and vasomotor symp-
toms (VMS).5–10 VMS, such as hot flashes and night
sweats, are primarily thermoregulatory phenomena and
are the main cause of sleep problems.3,11 Although VMS
are a hallmark of perimenopause, they can persist for
several years after the last menstrual period. Therefore,
they may continue to affect sleep even in advanced age.12
However, while all aging women experience major hor-
monal changes, not all women experience increased sleep
problems.13 This suggests that genetic and environmental
factors may play a role in the exacerbation of sleep pro-
blems among middle-aged and older women.14–18
Epigenetic modifications are increasingly recognized
as potential mechanisms underlying the etiology and phe-
notypic variation of multiple diseases.19 It has also been
suggested that epigenetic modifications may constitute
underlying mechanisms of the gene-environment interplay
affecting sleep and menopause-related symptoms.14,20,21
DNA methylation is a key epigenetic mechanism, which
regulates gene expression through DNA modifications at
cytosines in cytosine-guanine dinucleotides (CpGs).22
Increased DNA methylation of regulatory regions of estro-
gen receptor (ER) genes has been shown to decrease levels
of ERs.6,23,24 ERs mediate the effects of estrogens in the
body, including the estrogenic contributions to the control
of circadian rhythms and body temperature.25–27 While the
ERα and the ERβ mainly mediate the genomic effects of
estrogens, the more recently discovered G protein-coupled
estrogen receptor 1 (GPER) mediates rapid non-genomic
estrogen effects.28 Several lines of evidence from animal
studies indicate that decreased levels of the three ERs may
contribute to increase sleep problems and VMS.29–31
To the best of our knowledge, no study has yet inves-
tigated the associations between ER gene methylation and
sleep problems in middle-aged and older women. DNA
methylation levels of specific regions of ER genes may
contribute to alter sleep quality among women as they
reach midlife. Therefore, in this study, we hypothesized
that increased levels of ER gene methylation would be
associated with increased sleep problems in healthy pre-,
peri-, and postmenopausal women, either directly, or indir-
ectly through VMS. We focused on the ERα gene (ESR1)
and GPER gene (GPER) based on knowledge of the
involvement of both genomic and non-genomic estrogen
effects in sleep problems and VMS, and given the pre-
sumed greater role of ERα compared to ERβ in controlling
circadian rhythms and body temperature in women.29,32
Materials and Methods
Inclusion and Exclusion Criteria
Women who took part in this study were recruited in the
context of a larger investigation, the “Women 40+ Healthy
Aging Study”.33–36 Women were recruited using flyers,
social media (eg: Facebook), and journal articles. The
prospective participants completed an online self-
screening to verify their eligibility for the study. Women
were included in the study if they reported being free of
any acute or chronic somatic disease or mental disorder,
and if they had not received any psychotherapeutic or
psychopharmacological treatment during the last 6
months. In addition, women had to report good, very
good, or excellent subjective health status. Further exclu-
sion criteria were a pregnancy in the last 6 months, meno-
pause due to surgical removal of the ovaries or the uterus,
premature menopause, current use of oral contraceptives
or hormone therapy. After completion of the online self-
screening, eligible women were reached telephonically by
a member of the study team. The telephone call aimed,
first, to ensure that only women suitable for the study were
included, and second, to answer open questions about the
study procedure. Participants were invited to a laboratory
session during which saliva and blood samples were col-
lected. All sessions started at 7:45 a.m. and followed
a standardized protocol.
Participants
In total, 130 healthy Caucasian women aged 40–73 years
took part in the study. The women lived in Switzerland, and
the majority were Swiss or from a German-speaking neigh-
boring country. Most of the women were married or living
together with their partner (68.5%), and had vocational edu-
cation or a college/university degree (79.2%). Participants
were divided into three subgroups with respect to their MS
according to the Stages of Reproductive Aging Workshop
+10 (STRAW) criteria:37 1) premenopausal (39.2%, n= 51),
if the menstrual cycle was regular, 2) perimenopausal
(12.3%, n= 16), if the cycle length was variable, with
a variability among cycles of at least 7 days, or if the interval
between cycles was > 60 days, and 3) postmenopausal
(48.5%, n= 63), if no bleeding had occurred in at least the
last 12 months. Women using hormone therapies for redu-
cing menopausal symptoms were excluded during the online
self-screening. After enrolment, women were screened for
the use of other medications. Five women reported taking
botanical therapies such as Cimifemin® (2), Cimifemin®
Gardini et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Nature and Science of Sleep 2020:12526
forte (1), Premens (1), and a plant-based preparation (no
pharmaceutical name provided; 1). In addition, one woman
reported taking Eltroxin (hypothyroidism) and one woman
reported taking Tamoxifen (breast cancer prevention). The
results were not affected by the exclusion of these partici-
pants from the statistical analyses, and the sample of this
study includes participants reporting the use of the above-
mentioned medications. After receiving written and oral
information about the study, all participants signed written
informed consent forms. The study (BASEC Nr
2016–01591) was evaluated by the cantonal ethics commit-
tee of the Canton of Zürich (KEK Zürich, Zürich,
Switzerland). Approval from the cantonal ethics committee
was not required because the assessment of relationships
between biological and physiological parameters in healthy
aging individuals was not considered to fall within the scope
of the “Humanforschungsgesetz” (HFG) (Art. 2 HFG and
Art. 3 HFG).
Sleep Problems
Sleep problems were assessed using the German version of
the Pittsburgh Sleep Quality Index (PSQI).38 The scale
assesses sleep problems over a one-month time interval
and comprises 19 items combined into seven component
scores: perceived sleep quality (“how would you rate your
sleep quality overall”?), sleep latency (eg: “cannot get to
sleep within 30 minutes”), sleep duration (“how many
hours of actual sleep do you get at night”?), sleep effi-
ciency (number of hours slept/number of hours spent in
bed), sleep disturbances (eg: “wake up in the middle of the
night or early morning”, “had bad dreams”), use of sleep
medication (eg: “how often have you taken medicines to
help you sleep”?), and daytime dysfunction (eg: “how
much of a problem has it been for you to keep up enough
enthusiasm to get things done?”). Each component is
weighted equally from 0 to 3, and the seven component
scores are summed up to obtain a total score ranging from
0 to 21. A score above 5 is considered a marker of sleep
problems. The single total score is frequently used in the
literature, and acceptable reliability and validity in differ-
ent populations have been reported.39 However, the model
including only perceived sleep quality, sleep efficiency and
daytime dysfunction (3-factor model) seems to better
reflect good versus poor sleep quality in healthy peri-
and early postmenopausal women with hot flashes, and
in older adults.39,40 Therefore, in the statistical analyses
of the present study, we used both the total score and the
3-factor model of the PSQI.
Descriptive statistics of sleep problems in the overall sam-
ple and based on menopausal groups are reported in Table 1.
Vasomotor Symptoms
VMS were measured using one item (“hot flashes/sweat-
ing”) of the somato-vegetative subscale of the German
version of the Menopause Rating Scale (MRS).41 VMS
are rated on a 5-point Likert scale, ranging from “0” (no
symptoms) to “4” (very severe symptoms). The prevalence
of VMS was assessed as follows: 0 (no symptoms), 1–4
(symptoms). Descriptive statistics of VMS for all women
and separately for menopausal groups are reported in
Table 1.
Blood Sampling
Blood samples were collected at 8:00 am during the labora-
tory session at the University of Zurich under standardized
conditions. For pre- and perimenopausal women, sampling
was conducted in the early follicular phase. Blood was
collected from fingertips and spotted onto S&S 903
Whatman® paper cards (GE Healthcare, Little Chalfont,
Buckinghamshire, United Kingdom), following the manu-
facturer’s instructions. Blood spots were dried at room tem-
perature for approximately 3 h. Dried blood spots (DBS)
were stored at −20°C until biochemical analysis.
Table 1 Descriptive Statistics
N All PRE PERI POST
130 51 16 63
Sleep problems (mean/SD) 4.8/2.5 4.2/2.4 5.8/2.6 5/2.5
VMS (mean/SD) 1.8/1 1.3/0.5 2.4/1.1 2/1.2
ESR1 methylation (%;
mean/SD)
76.7/12 79/8.4 78.1/7.9 74.5/14.7
GPERmethylation (%; mean/
DS)









BMI (kg/m2; mean/SD) 23/3.6 22.8/3.9 21.5/3.4 23.7/3.3
E2 (nmol/L; mean/SD) 5.6/4.5 8.2/4.7 5.7/4.5 3.7/3.2
Depressive symptoms
(mean/SD)
8.3/5.9 7.4/5.5 10.1/7.3 8.6/5.7
Caffeine (cups/day; mean/
SD)
2.5/2 2.2/0.2 2.1/0.4 2.7/0.1
Note: The percentages of ESR1 and GPER methylation correspond to the mean of
methylation percentages of the 9 CpGs and 22 CpGs assessed in the ESR1 and GPER
sequences, respectively.
Abbreviations: PRE, premenopausal, PERI, perimenopausal, POST, postmenopau-
sal, VMS, vasomotor symptoms, ESR1, estrogen receptor 1 gene, GPER, G protein-
coupled estrogen receptor gene, BMI, body mass index, E2, estradiol, SD, standard
deviation.
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Genomic DNAwas extracted from DBS, using the QIAamp
DNA Investigator Kit (QIAGEN, Hilden, Germany), accord-
ing to the manufacturer’s instructions, and eluted in a final
volume of 30 μL of RNase-free water. We obtained a total
DNA yield ranging from 41 to 168 ng, as measured with
Qubit (Thermo Fischer Scientific, Waltham, MA, USA). The
DBS technology was reported to provide highly reliable
results in the context of methylation studies.42 Genomic
DNA (41–168 ng) was bisulfite-converted using the EZ 96-
DNA Methylation-Gold kit (Zymo Research, Irvine, CA,
USA) and eluted in 20 ul of water. A first amplification was
performed on the bisulfite-converted DNA using the Kapa
HIFI Uracil+ master mix and primers that were designed
manually or using the MethPrimer software.43 Primers
(Table 2) included the universal primer sequences CS1/CS2
at the 5ʹ ends of the forward and reverse primers, and were
designed in order to target a specific sequence of the ESR1
shore of promoter C (hg 38; chr6:151805523–151805822,
Figure 1A) and the GPER promoter (hg 38; chr7:1087059
−1087533, Figure 1B). DNA methylation in these regions
was previously associated with altered gene expression and
function.44,45 The PCR was performed with the following
parameters: 95°C for 3 min [98°C for 20 sec – annealing
temperature for 15 sec – 72°C for 15 sec] x 40 cycles, 72°C
for 40 sec. In order to certify that primers were specifically
amplifying bisulfite-converted DNA, genomic DNA was
included in the PCR, and complete conversion was con-
firmed by including wild primers. Next, the PCR amplicons
were purified using the E-gels 2% size selection (Thermo
Fisher Scientific, Waltham, MA, USA). Purified amplicons
were indexed with a single barcode (Fluidigm, San
Francisco, California, USA) using a second PCR of 10 cycles
(annealing temperature, 60°C). Indexed amplicons were
pooled and again purified. The purified library was then
quantified using the Agilent 2200 Tape Station instrument,
with HS DNA 1000 reagents (Agilent Scientific Instruments,
Santa Clara, CA, USA), and finally diluted to the concentra-
tion of 2nM. The final library was denatured in NaOH,mixed
with 12% PhiX, diluted to 12 pM in HT1 buffer, and finally
sequenced on an Illumina MiSeq sequencer using the v3 kit
(300 base pairs paired-end).
As described previously, adaptors and primers were
trimmed from the reads using the default settings of
Trimmomatic v0.35 (licensed under GPL V3 and available
at http://www.usadellab.org/cms/index.php?page=trimmo
matic), and low-quality reads defined by a Phred quality
score <30 were also discarded.47,48 Using Bismark program
(v0.19.0), the remaining sequencing reads were aligned to
the target regions and the number of unconverted and con-
verted cytosine was extracted for each interrogated CpG.
After summing up counts of unconverted and converted
cytosine for each CpG, we removed all samples showing
a coverage (=total count) lower than 100x.47 For ESR1, six
samples did not reach the 100x threshold and were therefore
excluded. For the remaining samples, coverage ranged from
157 to 42ʹ709 (Mean= 6ʹ5601, SD= 5ʹ968). The coverage of
most samples for GPER was less than 100x, and only 34
samples could be retained in the analyses. For these 34
samples, coverage ranged from 350 to 39ʹ942 (Mean=
10ʹ647, SD= 9553). The methylation percentage for each
CpG was calculated as the unconverted (cytosine) read
count divided by the total read count (cytosine + thymine).
The ESR1 shore and GPER methylation data are
openly available in “Dryad” at https://doi.org/10.5061/
dryad.51c59zw51.
One CpG cluster was identified for ESR1, and therefore
the mean of the nine assessed CpGs was used in the
statistical analyses. For GPER, two main clusters were
identified. However, the results were similar when using
the two clusters or the mean of all 22 CpGs assessed for
GPER. Therefore, only results obtained using the mean
level across all 22 CpGs are presented in this study.
Descriptive statistics of ESR1 and GPER methylation
Table 2 PCR Primers Used for Amplification of DNA Sequences in the ESR1 and GPER











Note: Universal primer CS1= ACACTGACGACATGGTTCTACA, universal primer CS2= TACGGTAGCAGAGACTTGGTCT.
Abbreviations: PCR, polymerase chain reaction; ESR1, estrogen receptor alpha gene; GPER, G protein-coupled estrogen receptor gene; GRCh38, Genome Reference
Consortium Human Build 38 Organism; Ta, annealing temperature.
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levels are reported in Table 1 for the entire sample and the
three menopausal stages, respectively.
Potential Covariates and Cofounders
In the statistical analyses we adjusted for age, MS, body
mass index (BMI), levels of estradiol (E2), depressive symp-
toms, and caffeine consumption.8,9,49-57 Depressive symp-
toms were assessed using the German version of the Center
for Epidemiological Studies Depression scale (CES-D),
which is a commonly used self-report measure of depressed
symptoms during the past one to 2 weeks.58 It consists of 20
items (eg, “I felt hopeful about the future”, “I felt that people
disliked me”), rated on a 4-point Likert scale ranging from 0
(rarely or none of the time [less than 1 day]) to 3 (most or all
of the time [five to 7 days]). The total score can range from 0
to 60, with higher scores indicating higher depressive symp-
toms. A cut-off score of 16 or above is often used as
a marker of risk for clinical depression.58 Levels of E2
concentrations were measured in saliva using an enzyme-
linked immunosorbent assay (IBL international, Hamburg,
Germany), following the manufacturer’s instructions. Saliva
samples were collected at 8:00 am into 2-mL SaliCaps (IBL
International GmbH, Hamburg, Germany) immediately
before the collection of blood samples. Intra- and inter-
assay coefficients were below 13.3% and 14.8%, respec-
tively, and the assay’s analytical sensitivity was 1.1
pmol/L. Values greater than three standard deviations around

















Figure 1 Schematic figures of ESR1 (A) and GPER (B) promoter regions. (A) The DNA sequence of ESR1, chr6: 151805523–151805822, is located in a CpG island shore of
promoter C, and it has been described as an enhancer (ID GH06J151804) of promoter A.44 This region has been reported in humans and rats by Champagne et al, 2006,23
Gardini et al, 2020,35 Ianov et al, 2017,46 and Tsuboi et al, 2017.44 (B) The DNA sequence of GPER, chr7:1087059–1087533 is located in a CpG island across exons 1 and 2.
This region has been assessed in Weissenborn et al, 2017.45 White boxes represent exons or promoter regions. Underlined sequences correspond to the primers position.
Bold “CG” correspond to the Interrogated CpGs.
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removed from the analyses. Salivary E2 strongly correlates
with free serum E2, which is the portion available for
estrogenic effects.59,60 BMI was calculated by dividing the
weight in kilograms by the height in meters squared, and
caffeine consumption was determined as the number of cups
of coffee the women drink per day.
Procedure and Statistical Analyses
Descriptive statistics were calculated to assess the prevalence
and severity of sleep problems and VMS among the three
menopausal groups (pre-, peri and postmenopausal women).
We used Chi-squared test in order to test the prevalence of
sleep problems and VMS, and one-way analysis of variance
(ANOVA) to test their severity. In the Chi-square test post-
hoc analysis, p-values were estimated from unstandardized
Z values, according to García-perez et al (2003).61 A p-value
below 0.05 was considered statistically significant.
In order to assess the effects of ESR1/GPER methylation
on sleep problems, considering VMS as potential mediators,
we conducted simple mediation analyses using the
PROCESS macro (model 4)62 in SPSS. The mediation
model allows the examination of the independent contribu-
tion of direct and indirect effects through three paths (ai, bi,
c’, see Figure 2): Path ai represents the association between
the predictor (X) and the mediator (Mi), path bi represents
the association between Mi and the outcome variable (Y),
and path c’ represents the direct effect of X on Y, after
adjusting for all other variables included in the model.
Finally, the indirect effect of X on Y throughMi is defined as
aixbi. Direct and indirect effects were assessed using boot-
strapping, with the b coefficient providing an index of the
magnitude of the effect. Bootstrapping generated
a confidence interval (CI). When the 95% asymmetric CI
did not include the value 0, direct and indirect effects were
considered significant. Bootstrapping has the advantages of
not requiring normal distribution of data and of a low
vulnerability to type 1 error.62 In a second step, MS was
dummy-coded, with the premenopausal group (compared to
peri- and postmenopausal groups) and perimenopausal and
postmenopausal groups (compared to the premenopausal
group) as dummies, to investigate whether effects of the
mediation analysis differed between premenopausal women
and the group including peri- and postmenopausal women.
All analyses were conducted using SPSS (IBM Statistics,
version 24.0, Armonk, NY: IBM Corp.).
Results
Levels of mean methylation across the investigated CpGs
of ESR1 and GPER for the three menopausal groups are
provided in Table 1. In addition, all variables assessed in
this study are provided in this table.
Descriptive Statistics of Sleep Problems
Among Menopausal Groups
Almost one third of the sample (30.5%) experienced sleep
problems (score of PSQI > 5) during the previous month.
Sleep problems were reported by 24% (n= 12) of premeno-
pausal women, 31.3% (n= 5) of perimenopausal women, and
35.5.% (n= 22) of postmenopausal women. The difference in
the prevalence of sleep problems among the three menopau-
sal groups was not statistically significant [χ2 (2, N= 128)=
1.73, p= 0.421]. However, there was a trend toward signifi-
cance regarding the difference in the severity of sleep pro-
blems among the groups [F(2125)= 2.94, p= 0.056], with
greater sleep problems in peri- (p= 0.028) and postmenopau-
sal women (p= 0.087) compared to premenopausal women.
Descriptive Statistics of Vasomotor
Symptoms Among Menopausal Groups
VMS were reported by 48.1% of all women. VMS were
experienced by 27% (n= 14) of premenopausal women,
81.3% (n= 13) of perimenopausal women, and 56.5%
(n= 35) of postmenopausal women. Among the three groups,
there was a statistically significant difference in the prevalence
of VMS [χ2 (2, N= 129)= 17.49, p< 0.001]. The number of
premenopausal women experiencing VMS was significantly
lower than the number of peri- and postmenopausal women
experiencing VMS (p< 0.001). The difference in the severity
of VMS among menopausal groups was also statistically
significant [F (2126)= 10.38, p< 0.001], with peri-
(p< 0.001) and postmenopausal women (p< 0.001) reporting
greater VMS severity compared to premenopausal women.
No significant difference in VMS severity was detected
between peri- and postmenopausal women (p= 0.130).
ESR1 Methylation and Sleep Problems
Using the total score of the PSQI as outcome variable, the
results indicated that ESR1 methylation predicted sleep pro-





Figure 2 Path diagram (Macro Model 4) according to Hayes (2017).62
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0.0299]), while the direct effect of ESR1 methylation on
sleep problems was not significant (b= 0.025, 95% CI
[−.0100, 0.0597], Figure 3). The results of this mediation
model are presented in Table 3. The results of the sensitivity
analysis indicated that most of the mediation effect came
from peri- and postmenopausal women (b= 0.0127, 95% CI
[0.0005, 0.0246]), compared to premenopausal women
(b= 0.0045, 95% CI [−.0020, 0.0121]).
Similar results were obtained when using the 3-factor
model. The indirect effect of ESR1methylation on the global
scores of perceived sleep quality, sleep efficiency and day-
time dysfunction through VMS was statistically significant
(b= 0.007, 95% CI [0.0014, 0.0187]), while the direct effect
was not significant (b= 0.011, 95% CI [−.0103, 0.0324]).
GPER Methylation and Sleep Problems
Using the total score of the PSQI as outcome variable, the
results indicated that GPER methylation was not predictive
of sleep problems, either directly (b= 0.073, t(23)= 1.08,
95% CI [−.0664, 0.2124]), or indirectly through VMS
(b= −.037, 95% CI [−.1083, 0.0416], Figure 4). The results
of this mediation model are presented in Table 4.
Likewise, when testing the effect of GPER methylation






Figure 3 Path diagram of the mediation model (Macro Model 4),62 illustrating the associations between ESR1 methylation (X) and sleep disturbances (Y) through VMS (Mi).
Estradiol (E2), menopausal status (MS), depressive symptoms, body mass index (BMI), age and caffeine consumption were included in the model and controlled in each of the
three paths (ai, bi, c’). Values outside parentheses= unstandardized b coefficient; values in parentheses= standard error; *= p-value < 0.05; **= p-value < 0.01.
Abbreviations: ESR1-m, estrogen receptor 1 methylation; VMS, vasomotor symptoms.
Table 3 Results of the Mediation Model with ESR1 Methylation as Predictor, 95% Bias-Corrected Confidence Interval Predicting Sleep
Quality
Outcome Variable: VMS b se t p LLCI ULCI
ESR1-m (ai) 0.0175 0.0078 2.2550 0.0261 0.0021 0.0329
CV
Age −.0516 0.0169 −3.0573 0.0028 −.0850 −.0182
MS 0.7049 0.1640 4.2969 0.0000 0.3798 1.0300
BMI 0.0194 0.0149 1.2970 0.1974 −.0102 0.0490
E2 −.0018 0.0224 −.0790 0.9372 −.0462 0.0427
Depressive symptoms −.0151 0.0155 −.9704 0.3340 −.0458 0.0157
Caffeine 0.0201 0.0575 0.3502 0.7269 −.0938 0.1340
Outcome variable: sleep problems (PSQI)
VMS (bi) 0.6301 0.2112 2.9837 0.0035 0.2116 1.0487
CV
Age 0.0586 0.0389 1.5055 0.1351 −.0186 0.1358
MS −.3619 0.3927 −.9215 0.3588 −1.1401 0.4164
BMI 0.0178 0.0333 0.5331 0.5950 −.0483 0.0838
E2 0.0147 0.0497 0.2962 0.7676 −.0838 0.1132
Depressive symptoms 0.2033 0.0345 5.8904 0.0000 0.1349 0.2717
Caffeine −.2224 0.1274 −1.7456 0.0837 −.4748 0.0301
Direct/indirect effects on sleep problems (PSQI)
Direct effect (c’) 0.0249 0.0176 1.4159 0.1597 −.0100 0.0597
Indirect effect (aixbi) 0.0110 0.0073 0.0013 0.0299
Notes: ai represents the association between ESR1-m and VMS; bi represents the association between VMS and sleep quality; c’ represents the direct effect of ESR1-m on Y,
after adjusting for all other variables included in the model; aixbi represents the indirect effect of ESR1-m on sleep quality through VMS; b represents the unstandardized
regression coefficient.
Abbreviations: se, standard error, BootLLCI, bootstrapping lower limit confidence interval; BootULCI, bootstrapping upper limit confidence interval; VMS, vasomotor
symptoms, ESR1-m, estrogen receptor alpha gene methylation; CV, control variables; MS, menopausal status; BMI, body mass index; E2, estradiol.
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GPER methylation on the global scores of perceived sleep
quality, sleep efficiency and daytime dysfunction was not
significant (b= 0.038, t(23)= 0.84, 95% CI [−.0544,
0.1295]), and nor was the indirect effect through VMS
(b= −.023, 95% CI [−.0722, 0.0287]).
Discussion
In the present study, we examined the associations
between ESR1/GPER methylation and sleep problems in
healthy women aged 40–73 years. No direct associations
between ESR1/GPER methylation and sleep problems
were detected. However, we found that increased levels
of ESR1 methylation were predictive of increased severity
of VMS, which in turn predicted increased sleep problems.
These associations were significant even if potential
cofounders such as age, MS, E2, and medical conditions
were controlled.3,11,44,54-56,63
The idea that epigenetic modifications of ER genes may
be key drivers of the onset and emergence of perimenopausal
symptoms, such as VMS, has been previously suggested.21
One potential mechanism contributing to altered epigenetic
patterns of ER genes may be the lifetime action of social and
environmental determinants. For instance, early exposure to






Figure 4 Path diagram of the mediation model (Macro Model 4),62 illustrating the associations between GPER methylation (X) and sleep disturbances (Y) through VMS (Mi).
Estradiol (E2), menopausal status (MS), depressive symptoms, body mass index (BMI), age and caffeine consumption were included in the model and controlled in each of the
three paths (ai, bi, c’). Values outside parentheses= unstandardized b coefficient; values in parentheses= standard error.
Abbreviations: GPER-m, G protein-coupled estrogen receptor methylation; VMS, vasomotor symptoms.
Table 4 Results of the Mediation Model with GPER Methylation as Predictor, 95% Bias-Corrected Confidence Interval Predicting Sleep
Quality
Outcome Variable: VMS b se t p LLCI ULCI
GPER-m (ai) −.0396 0.0262 −1.5117 0.1437 −.0937 0.0145
CV
Age −.0749 0.0353 −2.1208 0.0445 −.1477 −.0020
MS 0.7074 0.3276 2.1596 0.0410 0.0313 1.3836
BMI −.0210 0.0245 −.8555 0.4007 −.0716 0.0296
E2 −.0478 0.0414 −1.1542 0.2598 −.1332 0.0376
Depressive symptoms −.0228 0.0304 −.7485 0.4614 −.0856 0.0400
Caffeine 0.2073 0.1481 1.3999 0.1743 −.0983 0.5129
Outcome variable: sleep problems (PSQI)
VMS (bi) 0.9248 0.5017 1.8434 0.0782 −.1131 1.9627
CV
Age 0.1699 0.0945 1.7971 0.0855 −.0257 0.3655
MS −1.2543 0.8799 −1.4256 0.1674 −3.0746 0.5659
BMI −.0036 0.0612 −.0594 0.9531 −.1302 0.1229
E2 0.0183 0.1045 0.1751 0.8625 0.1978 0.2344
Depressive symptoms 0.2018 0.0756 2.6686 0.0137 0.0454 0.3583
Caffeine −.6193 0.3785 −1.6360 0.1155 −1.4023 0.1638
Direct/indirect effects on sleep problems (PSQI)
Direct effect (c’) 0.0730 0.0674 1.0834 0.2899 −.0664 0.2124
Indirect effect (aixbi) −.0366 0.0367 −.1083 0.0416
Notes: ai represents the association between GPER-m and VMS; bi represents the association between VMS and sleep quality; c’ represents the direct effect of GPER-m on Y,
after adjusting for all other variables included in the model; aixbi represents the indirect effect of GPER-m on sleep quality through VMS; b represents the unstandardized
regression coefficient.
Abbreviations: se, standard error, BootLLCI, bootstrapping lower limit confidence interval; BootULCI, bootstrapping upper limit confidence interval; VMS, vasomotor
symptoms, GPER-m, G protein-coupled estrogen receptor gene methylation; CV, control variables; MS, menopausal status; BMI, body mass index; E2, estradiol.
Gardini et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Nature and Science of Sleep 2020:12532
nutrition) has been linked to altered ESR1
methylation.6,23,33,64Most interestingly, early life adversities,
such as abuse and neglect, have been previously linked to
increased ESR1methylation in rat,23 and women,33 as well as
to increased VMS among midlife women.65
The Study of Women Across the Nation (SWAN), asses-
sing sleep quality in a multi-ethnic sample of 3ʹ045 women
in the US, showed that the prevalence of sleep disorders
ranged from 16% to 42% in premenopausal women, from
39% to 47% in perimenopausal women, and from 35% to
60% in postmenopausal women, with Caucasian women
reporting the highest rates.66 In our study, sleep problems
with PSQI scores >5 were reported by 24% of premeno-
pausal women, 31.3% of perimenopausal women and
35.5% of postmenopausal women. The characteristics of
our entirely healthy sample may explain the slightly lower
prevalence of poor sleep identified in the present study.11
This may also contribute to explain the smaller direct effect
of ESR1 methylation on sleep problems, compared to the
indirect effect mediated by VMS. The prevalence of VMS
among the participating women was comparable with the
results reported by the SWAN, which indicated that up to
80% of peri- and postmenopausal women experience
VMS.49 In both the present study and previous studies,
VMS were strongly associated with sleep problems.3
Together, these results may point to VMS as a primary
cause of sleep problems also in healthy women.
The assessment of epigenetic modifications in peripheral
tissues, such as blood, is increasingly seen as an important
source of biomarkers in health and disease. In addition, as
epigenetic signatures are mitotically heritable and yet rever-
sible, their correction holds considerable therapeutic
potential.67,68 The clinical implications of ESR1 methylation
in VMS may merit further investigation. For instance, long-
itudinal studies which assess the status of ESR1 methylation
before the perimenopausal phase, and which monitor the
development of VMS, may provide information regarding
the potential of ESR1 methylation as a predictive marker of
VMS. In the present study, we used DNA extracted from
peripheral blood collected on dried blood spots (DBS). The
DBS technology has been suggested as a promising tool in
the context of research on biomarkers.69 Its advantages
include long-term storage of samples even at room tempera-
ture, and ease of transportation.70
Although VMS may be primarily neurological symp-
toms involving brain regions such as hypothalamic areas,
studying DNA methylation in the brain relies on post-
mortem tissues, which has several implications in terms
of impracticality.71,72 Therefore, peripheral tissues such as
blood, buccal cells and saliva are currently used as a proxy
of the brain in methylation studies.73,74 Studies using
peripheral tissues as a surrogate have demonstrated how
specific methylation signatures are associated with disor-
ders affecting the brain.75 In addition, although DNA
methylation is tissue-specific, it has been demonstrated
that at some CpGs, DNA methylation variance is more
closely linked to individual specificity than to tissue
specificity.76 Online tools have been developed which
enable a comparison of inter-individual methylation var-
iance between peripheral tissues and the brain.76–78 Using
the online tool provided by Hannon et al (2015),76 we
found that methylation of CpGs located in the assessed
DNA region of ESR1 was strongly correlated between
blood and brain in the same individuals.35 Therefore,
methylation variations in blood may reflect methylation
variations in the brain, for the assessed CpGs of ESR1.
Strengths and Limitations
To the best of our knowledge, this is the first study to examine
and highlight associations between ESR1 methylation and
sleep problems through VMS in healthy middle-aged and
older women. In this study, we assessed subjective sleep
through the PSQI,38,79 while objective parameters of sleep
were not measured. Indeed, questions have been raised
regarding the validity of laboratory sleep assessments in
women experiencing VMS.80 For instance, evidence sup-
porting an association between objective measures of sleep
and VMS is limited and contradictory, despite the association
between sleep problems and VMS is well known.81
However, as subjective and objective sleep measurements
may capture different aspects of sleep,80,82 objective sleep
assessments, such as polysomnography or actigraphy, may
be needed to better elucidate the nature of the association
between ER genes methylation and sleep.
Our sample included only healthy Caucasian women. On
the one hand, as both the race and health status may affect
subjective sleep difficulties and self-perceived menopausal
symptoms,3,53,66 the characteristics of our sample may help
to limit biases linked to race and disease factors. On the other
hand, our findings may not be generalizable to other racial/
ethnic groups and to the general population including women
with poor health. In addition, the sample of this study
included three menopausal groups, and the distribution of
participants among the three groups was not equal. In parti-
cular, the perimenopausal group included significantly fewer
participants than the pre- and postmenopausal groups. These
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considerations may limit comparison with other studies.
Furthermore, the sample size of GPER methylation, which
was strongly reduced compared to the sample size of ESR1
methylation. Therefore, the assessment ofGPERmethylation
in a larger sample may be useful in order to compare the
relative contribution of ESR1 and GPER methylation in the
associations with sleep problems and VMS. Finally, the fact
that we did not adjust for cell-type composition may also
constitute a limitation of this study, as cell-type composition
potentially affects levels of methylation in peripheral
blood.83
Conclusion
The main result of this study indicates that increased ESR1
methylation may be associated with VMS, which in turn
contribute to increased sleep problems in healthy middle-
aged and older women. Therefore, this study supports the
role of ESR1 in middle-aged and older women’s sleep
problems through epigenetic mechanisms. Clinical impli-
cations, such as the potential of ESR1 methylation as
a biomarker of VMS, may be evaluated in future
investigations.
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